192 related articles for article (PubMed ID: 35593784)
1. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
[TBL] [Abstract][Full Text] [Related]
2. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
[TBL] [Abstract][Full Text] [Related]
3. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
Zebenholzer K; Gall W; Wöber C
J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
[TBL] [Abstract][Full Text] [Related]
4. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
5. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S
Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962
[TBL] [Abstract][Full Text] [Related]
6. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
7. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
8. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans.
Petersen CL; Hougaard A; Gaist D; Hallas J
JAMA Neurol; 2024 Mar; 81(3):248-254. PubMed ID: 38315477
[TBL] [Abstract][Full Text] [Related]
9. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
[TBL] [Abstract][Full Text] [Related]
10. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
Perearnau P; Vuillemet F; Schick J; Weill G
Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
[TBL] [Abstract][Full Text] [Related]
11. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
[TBL] [Abstract][Full Text] [Related]
12. Twenty-five years of triptans - a nationwide population study.
Davidsson OB; Olofsson IA; Kogelman LJ; Andersen MA; Rostgaard K; Hjalgrim H; Olesen J; Hansen TF
Cephalalgia; 2021 Jul; 41(8):894-904. PubMed ID: 33583217
[TBL] [Abstract][Full Text] [Related]
13.
Martínez-Pías E; García-Azorín D; Minguez-Olaondo A; Trigo J; Sierra Á; Ruiz M; Guerrero ÁL
Expert Rev Neurother; 2021 Jan; 21(1):123-130. PubMed ID: 33111580
[No Abstract] [Full Text] [Related]
14. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database.
Huber CA; Agosti R; Näpflin M; Blozik E
Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):279-287. PubMed ID: 31828875
[TBL] [Abstract][Full Text] [Related]
16. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
17. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
[TBL] [Abstract][Full Text] [Related]
18. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
19. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
Lee JH; Shewale AR; Barthold D; Devine B
Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
[TBL] [Abstract][Full Text] [Related]
20. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
